ELZA and the Ocular Biome
“The eye, once thought sterile and immunoprivileged, is entangled in systemic crosstalk between microbial tenants and ocular health.”
Mark Hillen
January 20, 2026
“The eye, once thought sterile and immunoprivileged, is entangled in systemic crosstalk between microbial tenants and ocular health.”
A January 2026 The Ophthalmologist article outlines how personalised CXL is applied in three real-world scenarios: good vision, cataract planning, and markedly irregular corneas.
Dr. Dion Paridaens represented ELZA at VSOPRS Hanoi 2026, presenting expert surgical strategies for upper eyelid retraction in thyroid eye disease.
At Swiss Eye Week 2026 in Thun, Prof Farhad Hafezi contributed to ophthalmology education with lectures on corneal cross-linking and ectasia rehabilitation.
Prof Farhad Hafezi represented the ELZA Institute at Keracon 2025 in Goa, contributing invited lectures on evidence-based advances in corneal cross-linking and ectasia management.
Prof. Farhad Hafezi presented five-year outcomes and future directions of the sub400 protocol for thin cornea CXL at the KCXL Experts’ Meeting 2025 in Milan.
Emilio Torres-Netto reviewed the evolution of epi-on CXL at KCXL 2025, explaining early failures and how modern protocols now achieve clinically meaningful keratoconus stabilisation.
Prof. Hafezi presented new insights on PACK-CXL, ELZA-PACE, and epi-on CXL at EPOMEC 2025, shaping future keratoconus management.
Ten years after the First Global Consensus, the Second Global Consensus on Keratoconus—reported in EuroTimes—provides an updated, internationally agreed framework for diagnosis, staging, and management. Developed using a modified Delphi process, it reflects a shift from disease stabilisation alone toward individualized care that integrates modern diagnostics, optimized cross-linking strategies, and visual rehabilitation.
ECO-CAIRS, developed at ELZA, uses ultra-high-fluence CXL to optimize donor corneal ring segments for keratoconus surgery. Now published in JRS.
